Last kr268.50 SEK
Change Today +2.50 / 0.94%
Volume 5.2K
As of 11:29 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

235 East 42nd Street

New York, NY 10017

United States

Phone: 212-733-2323


rum Silver, Centrum Men’s and Women’s, Centrum Specialist, Centrum Flavor Burst, and Centrum Kids), Caltrate, and Emergen-C; Pain Management: Advil brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children’s Advil, Infants’ Advil and Advil Migraine), and ThermaCare; Respiratory: Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and Personal Care: ChapStick and Preparation H. Animal Health In 2013, the company completed the full disposition of its Animal Health business, which was a business that discovered, developed, manufactured and commercialized animal health medicines and vaccines. Research and Development The company spent $6.7 billion in 2013 on research and development expenses. Customers During 2013, the company’s major customers included McKesson, Inc.; Cardinal Health, Inc.; and AmerisourceBergen Corporation. Regulations The company’s activities are subject to the jurisdiction of other federal regulatory and enforcement departments and agencies, such as the Department of Health and Human Services (HHS) Office of the Inspector General (OIG), the Federal Trade Commission (FTC) (which also has the authority to regulate the advertising of consumer healthcare products, including OTC drugs and dietary supplements), the Department of Justice (DOJ) and the SEC. Significant Events In May 2014, Pfizer has entered a five year collaborative agreement with the Global Medical Excellence Cluster (GMEC) in the UK that will conduct research and develop new medicines aimed at rare diseases. In May 2014, The American College of Physicians (ACP), CECity, and Pfizer Inc. have announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. In May 2014, Neopharma announced that it had entered a partnership with Pfizer to locally manufacture selected pharmaceutical products in the UAE, in an effort to meet the unmet needs of patients in the region. In May 2014, BioRestorative Therapies, Inc. announced that it has entered into a two-year collaborative research agreement with Pfizer Inc. to study human brown adipose tissue and cell lines. In June 2014, X-Chem, Inc. announced a multi-target collaboration with Pfizer Inc. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases. In June 2014, Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. In June 2014, CliniWorks announced a strategic alliance between its I subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties' respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health. In August 2014, The Crohn's & Colitis Foundation of America (CCFA) announced an agreement with Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) to identify and support the potential development and translation of research in the area of inflammatory bowel disease (IBD). In September 2014, Circle Pharma, Inc. initiated two collaborations with Pfizer Inc. to develop cell permeable Macrocyclic Peptide Therapeutics. In September 2014, Pfizer Inc. and Kyowa Hakko Kirin announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. Pfizer


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:SS kr268.50 SEK +2.50

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $164.02 USD -1.87
Bayer AG €128.07 EUR +4.14
Gilead Sciences Inc $105.54 USD +0.40
Novartis AG SFr.85.50 CHF +1.20
Procter & Gamble Co/The $90.08 USD -1.54
View Industry Companies

Industry Analysis


Industry Average

Valuation PFE Industry Range
Price/Earnings 20.1x
Price/Sales 4.1x
Price/Book 2.6x
Price/Cash Flow 13.9x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at